Monia Ezzalfani
About
Monia Ezzalfani is a scholar working on Statistics and Probability, Economics and Econometrics and Oncology.
According to data from OpenAlex, Monia Ezzalfani has authored 21 papers receiving a total of 231 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Statistics and Probability, 7 papers in Economics and Econometrics and 6 papers in Oncology. Recurrent topics in Monia Ezzalfani's work include Statistical Methods in Clinical Trials (9 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Optimal Experimental Design Methods (5 papers). Monia Ezzalfani is often cited by papers focused on Statistical Methods in Clinical Trials (9 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Optimal Experimental Design Methods (5 papers). Monia Ezzalfani collaborates with scholars based in France, Belgium and Sweden. Monia Ezzalfani's co-authors include Xavier Paolettí, C. Le Tourneau, Sumithra J. Mandrekar, Rui Qin, Marie‐Cécile Le Deley, Sarah Zohar, Anne Vincent‐Salomon, Véronique Mosseri, Frédérique Berger and Delphine Loirat and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.
In The Last Decade
Monia Ezzalfani
20 papers receiving 224 citations
Peers
Monia Ezzalfani
Elisa Rizzo Italy
Thomas Gwise United States
Veronica Bunn United States
Tianle Hu United States
David Dejardin Belgium
Astrid Jullion Switzerland
Tomoyuki Kakizume Japan
Jiabu Ye United States
Anwar M. Hossain United States
Anne-Laure Vallier United Kingdom
Citations per year, relative to Monia Ezzalfani Monia Ezzalfani (= 1×)
peers
Elisa Rizzo
Countries citing papers authored by Monia Ezzalfani
Since
Specialization
Citations
This map shows the geographic impact of Monia Ezzalfani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monia Ezzalfani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monia Ezzalfani more than expected).
Fields of papers citing papers by Monia Ezzalfani
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Monia Ezzalfani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monia Ezzalfani. The network helps show where Monia Ezzalfani may publish in the future.
Co-authorship network of co-authors of Monia Ezzalfani
This figure shows the co-authorship network connecting the top 25 collaborators of Monia Ezzalfani. A scholar is included among the top collaborators of Monia Ezzalfani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monia Ezzalfani. Monia Ezzalfani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Astermark, Jan, et al.. (2023). Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes. Therapeutic Advances in Hematology. 14. 1564088461–1564088461.
2.
Pasi, John, Cédric Hermans, Zalmaï Hakimi, et al.. (2022). Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study. Therapeutic Advances in Hematology. 13. 1553997242–1553997242.
3.
Ezzalfani, Monia, Raphaël Porcher, Alexia Savignoni, et al.. (2021). Addressing the issue of bias in observational studies: Using instrumental variables and a quasi-randomization trial in an ESME research project. PLoS ONE. 16(9). e0255017–e0255017.
4.
Azzopardi, Nicolas, Claire Bonneau, Céline Desvignes, et al.. (2021). Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration. Clinical Pharmacology & Therapeutics. 110(1). 210–219.
5.
Astermark, Jan, Cédric Hermans, Monia Ezzalfani, et al.. (2021). rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B‐LONG using haemophilia‐specific quality of life questionnaires. Haemophilia. 28(1). 18–26.
6.
Kirova, Youlia, Delphine Loirat, Frédérique Berger, et al.. (2020). Abstract OT2-03-01: A phase one trial of olaparib with radiation therapy in patients with triple negative breast cancer: RADIOPARP. Cancer Research. 80(4_Supplement). OT2–3.
7.
Loap, Pierre, Delphine Loirat, Frédérique Berger, et al.. (2020). Combination of Olaparib and Radiation Therapy for Triple Negative Breast Cancer: Preliminary Results of the RADIOPARP Phase 1 Trial. International Journal of Radiation Oncology*Biology*Physics. 109(2). 436–440.
8.
Ezzalfani, Monia. (2019). How to design a dose-finding study on combined agents: Choice of design and development of R functions. PLoS ONE. 14(11). e0224940–e0224940.
9.
Ezzalfani, Monia, Manuel Rodrigues, J-Y Pierga, et al.. (2018). Abstract OT3-04-01: A phase I of olaparib with radiation therapy in patients with inflammatory, loco-regionally advanced or metastatic TNBC (triple negative breast cancer) or patient with operated TNBC with residual disease. Cancer Research. 78(4_Supplement). OT3–4.
10.
Ezzalfani, Monia, Tomasz Burzykowski, & Xavier Paolettí. (2018). Joint Modelling of a Binary and a Continuous Outcome Measured at Two Cycles to Determine the Optimal Dose. Journal of the Royal Statistical Society Series C (Applied Statistics). 68(2). 369–384.
11.
Ezzalfani, Monia, Suzette Delaloge, Raphaël Porcher, et al.. (2018). Addressing the issue of bias in observational studies : Instrumental variable & Quasi-trial in ESME Research program. Revue d Épidémiologie et de Santé Publique. 66. S141–S142.
12.
Ray‐Coquard, Isabelle, Véronique Corset, Christian Baudet, et al.. (2017). Actionable molecular alterations in advanced gynecologic malignancies: First results from the ProfiLER program (NCT01774409) in France. Annals of Oncology. 28. v333–v333.
13.
Delaloge, Suzette, Monia Ezzalfani, Véronique Dièras, et al.. (2017). Evolution of overall survival according to year of diagnosis (2008-2014) and subtypes, among 16703 metastatic breast cancer (MBC) patients included in the real-life "ESME" cohort.. Journal of Clinical Oncology. 35(15_suppl). 1078–1078.
14.
Trédan, Olivier, Véronique Corset, Qing Wang, et al.. (2017). Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the ProfiLER study.. Journal of Clinical Oncology. 35(18_suppl). LBA100–LBA100.
15.
Yin, Jun, Rui Qin, Monia Ezzalfani, Daniel J. Sargent, & Sumithra J. Mandrekar. (2016). A Bayesian dose‐finding design incorporating toxicity data from multiple treatment cycles. Statistics in Medicine. 36(1). 67–80.
16.
Paolettí, Xavier, Monia Ezzalfani, & C. Le Tourneau. (2015). Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials. Annals of Oncology. 26(9). 1808–1812.
17.
Ezzalfani, Monia, Audrey Emmanuelle Dugué, Caroline Mollévi, et al.. (2015). Le rôle des cohortes d’expansion dans les essais de phase I en cancérologie : des recommandations du HUB phase I. Bulletin du Cancer. 102(1). 73–82.
18.
Paolettí, Xavier, A. Doussau, Monia Ezzalfani, Elisa Rizzo, & Rodolphe Thiébaut. (2015). Dose finding with longitudinal data: simpler models, richer outcomes. Statistics in Medicine. 34(22). 2983–2998.
19.
Ezzalfani, Monia, Sarah Zohar, Rui Qin, Sumithra J. Mandrekar, & Marie‐Cécile Le Deley. (2013). Dose‐finding designs using a novel quasi‐continuous endpoint for multiple toxicities. Statistics in Medicine. 32(16). 2728–2746.
20.
Cuffe, Sinéad, Abderrahmane Bourredjem, Stephen L. Graziano, et al.. (2012). A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit From Adjuvant Platinum-Based Chemotherapy in Node-Negative Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 7(6). 963–972.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Elisa Rizzo Breakdown of academic impact, for papers by Thomas Gwise Breakdown of academic impact, for papers by Veronica Bunn Breakdown of academic impact, for papers by Tianle Hu Breakdown of academic impact, for papers by David Dejardin Breakdown of academic impact, for papers by Astrid Jullion Breakdown of academic impact, for papers by Tomoyuki Kakizume Breakdown of academic impact, for papers by Jiabu Ye Breakdown of academic impact, for papers by Anwar M. Hossain Breakdown of academic impact, for papers by Anne-Laure Vallier